A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
This research is an important next step for children and teenagers aged 6 to 17 who experience migraine headaches and have already been involved in an earlier study looking at a medication called eptinezumab. The main aim is to carefully check the long-term safety of eptinezumab when used by young people. Participants will continue to receive the study medication, with different groups receiving either a 100 mg or 300 mg dose, adjusted for their weight. Those who previously received a dummy treatment (placebo) will now be given one of the active doses. This study will help doctors understand how safe this treatment is over a longer period for young people with migraine.
En un coup d'œil
De quoi parle cette étude ?
This study is an extension of previous research, specifically for children and teenagers (aged 6 to 17) who get migraine headaches. These young people would have already taken part in an earlier study that looked at a new medication called eptinezumab for either chronic migraine (very frequent migraines) or episodic migraine (less frequent migraines).
The main purpose of this follow-up study is to keep a close eye on the long-term safety of eptinezumab. Researchers want to make sure it's safe for young people to use over a longer period. By continuing to observe participants, doctors can gather more information about any effects, good or bad, that might appear with ongoing use of the medicine.
Taking part helps doctors learn more about managing migraines in young people. This is important because migraines can significantly affect a child's life, including their schooling, friendships, and daily activities. Finding safe and effective treatments is a big step towards improving their quality of life.
Points clés
- This study is for children and teenagers (6-17) with migraines.
- It's an extension for those who were in a previous eptinezumab migraine study.
- The main goal is to check the long-term safety of eptinezumab.
- All participants will receive the active medication, not a placebo.
- Participation involves clinic visits, infusions, and health checks.
Qui peut être éligible ?
To join this study, you must be a child or teenager between 6 and 17 years old. Crucially, you must have already finished the first phase of an earlier study (called Study 19356A or Study 19357A) investigating eptinezumab for migraines. You would have completed all initial visits, including the one at Week 12, just before starting this new study.
There are some important reasons why you might not be able to join. If you had any health concerns or side effects during the first study that your doctor thinks could be risky for you to continue, you wouldn't be able to take part. This includes if you had a very serious allergic reaction during the previous study.
Also, if blood tests during the previous study showed certain problems with your liver, particularly if the levels of specific liver enzymes were very high or combined with high bilirubin levels, you would not be eligible for this extension study. Your doctor will carefully review your health information from the first study to make sure it's safe for you to continue.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Are you between 6 and 17 years old?
- Have you already finished an earlier migraine study (Study 19356A or 19357A) with eptinezumab?
- Did you complete all your visits in that previous study, including the Week 12 visit?
- Did your doctor say it's safe for you to continue with further study treatment, based on your previous study experience?
- Did you avoid any severe allergic reactions or specific liver problems during the last study?
En quoi consiste la participation ?
If you join this study, you will continue to receive the study medication, eptinezumab. If you were getting the active medication in the previous study, you'll generally continue on the same dose (either 100 mg or 300 mg, adjusted for your weight). If you received a dummy treatment (placebo) before, you'll now be randomly assigned to either the 100 mg or 300 mg dose of eptinezumab, also adjusted for your weight.
The medication is given through an infusion, which means it will be delivered directly into your vein. You will have regular visits to the clinic so the study team can monitor your health, check for any side effects, and see how you are responding to the treatment. These visits will likely include physical examinations, blood tests, and discussions about your migraines and overall well-being. The total duration of this extension study will be decided by the researchers, but the aim is to look at long-term safety.
Risques et avantages potentiels
Locations (64)
- Yale School of Medicine - The Scirex Clinical Research UnitCode postal vérifiéNew Haven, États-Unis· Recrutement
- New England Institute for Clinical Research (NEICR) - StamfordCode postal vérifiéStamford, États-Unis· Recrutement
- Sarkis Clinical Trials - GainsvilleCode postal vérifiéGainesville, États-Unis· Terminé
- NW FL Clinical Research Group, LLCCode postal vérifiéGulf Breeze, United States· Recrutement
- AGA Clinical TrialsCode postal vérifiéHialeah, États-Unis· Recrutement
- Axcess Medical Research - LoxahatcheeCode postal vérifiéLoxahatchee Groves, United States· Terminé
- University of South Florida (USF) - Tampa CampusCode postal vérifiéTampa, États-Unis· Recrutement
- University of Kentucky (UK) - Markey Cancer CenterCode postal vérifiéLexington, United States· Recrutement
- University of Maryland School of MedicineCode postal vérifiéBaltimore, États-Unis· Recrutement
- Michigan Headache & Neurological Institute (MHNI)Code postal vérifiéAnn Arbor, États-Unis· Terminé
- Corewell Health - Helen DeVos Children's Hospital (HDVCH) - Medical GeneticsCode postal vérifiéGrand Rapids, United States· Terminé
- Dent Neurosciences Research CenterCode postal vérifiéAmherst, United States· Terminé
Questions fréquentes
What is eptinezumab?
Eptinezumab is a medication being studied to help prevent migraine headaches in children and teenagers.
Qui peut participer à cette étude ?
Children and teenagers aged 6 to 17 who have previously completed an earlier study with eptinezumab for migraines.
Will I get a dummy treatment (placebo) in this study?
No, all participants in this study will receive the active medication, eptinezumab.
How is the medication given?
The medication is given as an infusion, meaning it goes directly into a vein, usually in your arm.
Pourquoi cette étude est-elle importante ?
It helps doctors understand the long-term safety of eptinezumab for young people with migraines and improve their treatment options.
Comment en savoir plus
Email contact via H. Lundbeck A/S
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.